

Di-George Syndrome

Dr Petra Jenkins

ACHD Cardiologist

Network Study Day 25.1.21



**Liverpool Heart and
Chest Hospital**
NHS Foundation Trust



Synonyms

- Chromosome 22q11 deletion
- VCFS
- CATCH 22
 - Cardiac Anomalies
 - Abnormal facies
 - Thymic Hypoplasia
 - Cleft Palate
 - Hypocalcaemia

All the same genetic basis > differing phenotype

History

- Angelo DiGeorge 1965 described
 - Thymic Hypoplasia
 - Congenital cardiac anomalies
- Kinouchi et al 1975 described
 - Conotruncal anomalies
 - Facial features
- Sprintzen et al 1977 described
 - Velocardiofacial syndrome (VCFS)



What is DiGeorge Syndrome?

- Caused by a genetic mutation on 22nd chromosome that results in the deletion of a portion of it
- Autosomal dominant immunodeficiency
- Results in poor development of several body systems
- The underlying cause is a shrunk or missing thymus gland

Incidence

- Around 1:4,000
- 8% of Cleft palates > most commonly associated genetic defect
- Constitutes 25% of all congenital cardiac defects
- Race: No predispositions identified
- Sex: Equal
- Age: Congenital

Causes


94% De-Novo deletions

(25% of parents of de-novo case found to carry same deletion)

- Unbalanced translocation from a balanced parent
- Del/Interstitial del of 10p13 – rare cause of DGS (type II)
- **Phenotypic variability** > disease severity + age of presentation.
- Environmental factors:
 - Maternal C₂H₅OH
 - Retinoid exposure
 - Uncontrolled DM in pregnancy

Genetics

- Deletion on long arm of Ch 22
- Deletion is long (2-3 Mb) in 95% of patients



Pathogenesis

- Deletion results in
 - **Defective migration** of the neural crest cells during 4th week of embryogenesis
 - **Developmental field defect** (involving the 3rd and 4th pharyngeal pouches) of:
 - The heart > CHD
 - Head and neck > Cleft + other ENT presentations
 - Thymus > Immunodeficiency
 - Parathyroid > Hypocalcaemia





Figure 1. The sites of origin, migration, and arrival of cranial neural crest cells. (A) Embryonic neural tube showing the mesencephalon, metencephalon, and rhombomeres, with the dorsal face of tube coloured to show the location of neural crest before migration. (B) Sagittal view of embryo, showing paths of migration of cranial crest cells. (C) Sagittal view of adult human, showing the origins of various cranial crest derivatives.



MES mesencephalon
MET metencephalon
FB forebrain
OP optic vesicle
R1 rhombomere 1
R2 rhombomere 2
R3 rhombomere 3
R4 rhombomere 4
R5 rhombomere 5

R6 rhombomere 6
R7 rhombomere 7
R8 rhombomere 8
PA1 first pharyngeal arch
PA2 second pharyngeal arch
PA3 third pharyngeal arch
PA4 fourth pharyngeal arch
PA6 sixth pharyngeal arch

IN incus
ML malleus
ST stapes

Origin of structures in adult organism

- Frontonasal process
- First pharyngeal arch
- Second pharyngeal arch
- Third pharyngeal arch
- Fourth pharyngeal arch

The Phenotype of Chromosome 22q11.2 Deletion Syndrome

- Cardiac anomaly 75%
 - TOF 20%
 - IAA 15%
 - Truncus arteriosus 8%
- Palatal anomaly 69-100%
- Hypocalcemia 17-60%
- Speech delay 75%
- Renal anomaly 36-37%
- Skeletal anomaly 17-19%
- Immunodeficiency 60-77%

Clinical Immunodeficiency

7% of all ages have significant, serious infections

9% have autoimmune disease

Older children and adults continue to get infections

27% recurrent sinusitis

25% recurrent otitis media

7% recurrent bronchitis

4% recurrent pneumonia

Tests, Limitations


- Cytogenetic analysis may detect del22q11 (a)
- FISH - suspected submicroscopic deletion (b)
- Molecular analysis using DNA probes from DiGeorge chromosomal region (DGCR) (c)



(a)



(b)



(c)

Tests, Limitations


- 5% of patients with clinical symptoms of del22q11 have normal cytogenetic studies and FISH
- May be a variant of deletions of DGCR which may be detectable on a research basis only

Genetic Counselling

- Parents
 - 94% have de novo del. of 22q11
 - 6% have inherited the 22q11del from a parent, thus both parents of an individual should have FISH testing
- Offspring
 - Of an individual with 22q11del have a 50% chance
 - If the parents of an individual have normal FISH, the recurrence risk is small, assuming a very low, and yet undefined risk of germ line mutation

Consultations and FU

- Multidisciplinary Team:
- Primary > Secondary > Tertiary
 - Geneticists
 - Psychiatrists
 - Immunologist
 - Otolaryngologist
 - Cardiologist > ACHD
 - Craniofacial specialist
 - Endocrinologist
 - Surgeons
 - Therapists and AHP
 - Health and Social care agencies




Advocacy, Education, Research Guidelines

Browser tabs: Digeorge max appeal - Bing, Adult Management Gui

Address bar: https://www.maxappeal.org.uk/knowledge/consensus_document/content.asp?s=44&p=109

Cookie notice: We use cookies on our website. Are you happy to continue? [Yes](#) [More Information](#)

 **Max Appeal!**

Supporting families affected by DiGeorge Syndrome, VCFS and 22q11.2 deletion

[Home](#) [Knowledge](#) [Awareness](#) [Research](#) [Archive](#) [What's On](#) [Fundraising](#) [Real People](#) [About Us](#) [Links](#) [Contact Us](#)

Covid-19

[Home](#) ▶ [Knowledge](#) ▶ [Consensus Document](#) ▶ [Adult Management Guidelines](#)

[A Bit of Background History](#)

[For Everyone](#)

[Early Years](#)

[School Years](#)

[Teens and Adults](#)

[Consensus Document](#)

- [For Parents and Carers](#)
- [For Professionals](#)
- [Spanish Translation of Con Doc](#)
- [Child Management Guidelines](#)
- [Adult Management Guidelines](#)
- [Adult 22q11DS Guidance for Health Professionals](#)

[22q11.2 Duplications](#)

[Glossary of Terms](#)

[Mental Health Disorders in 22q11 DS Leaflet](#)

[Information for Students Leaflets](#)

[Professionals](#)

Adult Management Guidelines

Practical Guideline for Managing Adults with 22q11 Deletion Syndrome

First published on-line on 8th January 2015.

REVIEW | [Genetics in Medicine](#)

Download: [Management Guidelines for Adults with 22q11DS](#)

Table 1 Recommendations for periodic assessments and health monitoring for adults with 22q11.2DS

Recommendations	Baseline workup at adult diagnosis or initial assessment at transition from pediatric care		Annual or biennial follow-up as an adult
	Complete	As needed	Complete
Genetic/general assessments and management			
Consultation with medical geneticist and/or clinicians experienced with 22q11.2DS	✓		✓
Genetic counseling ^a	✓		✓
Clinical genetic testing	✓ ^b		
Family planning and prenatal counseling		✓	
Other clinical assessments			
Comprehensive medical history	✓		
Systems review	✓		✓
Psychiatric assessment ^c	✓		
Cognitive and capacity assessments	✓		
Neurological assessment		✓	
Ophthalmological assessment		✓	
Orthopedic assessment		✓	
Family history	✓		✓
Physical examination (including for hygiene and care)	✓		✓
BMI/growth/nutritional assessment	✓		✓
Other investigations			
22q11.2DS-relevant laboratory tests ^d	✓		✓
Electrocardiography		✓	
Transthoracic echocardiography		✓ (If not previously performed)	
Abdominal ultrasound ^f		✓	
Electroencephalography		✓	
Other management			
Contraception and safe sex counseling	✓		✓
Counseling on Internet safety	✓		✓
Dental assessment	✓		
Audiology assessment	✓		
Other ^g	✓		

22q11.2DS, 22q11.2 deletion syndrome; BMI, body mass index.

^aDescribed in the text. ^bProband, offspring, and parents (siblings if parents unavailable). ^cIn addition to monitoring for changes (Table 2), includes assessment of

Digeorge max appeal - BingAdult 22q11DS Guidance foAdult_22q11DS_Guidan

https://www.maxappeal.org.uk/downloads/Adult_22q11DS_Guidance_for_Health_Professionals.pdf

1 of 3

Fit to pagePage viewRead aloudAdd notes

Max Appeal!

Supporting Families affected by DiGeorge Syndrome/VCFS/22q11.2 deletion

15 Meriden Avenue, Stourbridge,
West Midlands, DY8 4QN

Helpline: 0300 999 2211

info@maxappeal.org.uk

www.maxappeal.org.uk

Max Appeal UK

ADULT 22q11DS GUIDELINES FOR HEALTH PROFESSIONALS

Foreword

When diagnosed in childhood, 22q11 is sometimes managed by a multidisciplinary approach. Once the transition into adult hood is made however, or if the patient is diagnosed in adulthood then these safety nets are not available to them and this is where GP and other health professional services become vital for their life long care to be the link to all areas of support that are needed to help them live a long and productive life.

To help assist your patient with their care plan we would be grateful if you could spare a few minutes to familiarise yourself with the care recommendations contained within this document which has been written by Dr Alex Habel, a leading expert on the condition and founder of the 22q11 clinic at Great Ormond Street and Dr Dinakantha Kumaratne, Max Appeal trustee and immunologist at Addenbrooke's hospital.

by Mark Tripp, Trustee of Max Appeal

14:15
23/01/2021

Advertisement

Original Article | [Open Access](#) | Published: 03 January 2014

Towards a safety net for management of 22q11.2 deletion syndrome: guidelines for our times

[Alex Habel](#) , [Richard Herriot](#), [Dinakantha Kumararatne](#), [Jeremy Allgrove](#), [Kate Baker](#), [Helen Baxendale](#), [Frances Bu'Lock](#), [Helen Firth](#), [Andrew Gennery](#), [Anthony Holland](#), [Claire Illingworth](#), [Nigel Mercer](#), [Merel Pannebakker](#), [Andrew Parry](#), [Anne Roberts](#) & [Beverly Tsai-Goodman](#)

European Journal of Pediatrics **173**, 757–765(2014) | [Cite this article](#)

4751 Accesses | **38** Citations | **18** Altmetric | [Metrics](#)

Abstract

The commonest autosomal deletion, 22q11.2 deletion syndrome (22q11DS) is a multisystem disorder varying greatly in severity and age of identification between affected individuals.

Download PDF



Sections

Figures

References

Abstract

Introduction

Method

Presentations

Discussion

Conclusions

Abbreviations

References

Acknowledgments